Cardiac resynchronization therapy for prevention of heart failure events in elderly patients with left ventricular dysfunction.
Heart failure (HF) due to left ventricular (LV) systolic dysfunction contributes significantly to cardiovascular morbidity and is a major cause of mortality throughout the world. Its prevalence is increasing as the population ages. Age-related structural and functional changes of the heart in combination with multiple coexisting comorbid conditions significantly reduce cardiovascular reserve capacity and increase the risks of developing symptomatic HF in the elderly. Cardiac resynchronization therapy (CRT) has been demonstrated to reduce HF-related hospitalization as well as mortality and has become an important part of treatment for qualified patients with advanced HF. More recent studies showed a significant reduction in the risk of HF and mortality among CRT recipients with asymptomatic and mildly symptomatic HF (New York Heart Association functional class I–II), LV systolic dysfunction and widened QRS complex, supporting the notion that CRT may prevent or delay disease progression. Although data on the benefit of preventive CRT in the elderly are limited to retrospective subgroup analyses with relatively small numbers of elderly patients, accumulating data suggest that CRT confers similar or greater clinical benefit among elderly patients compared with their younger counterparts. As the proportion of elderly patient with LV systolic dysfunction is increasing dramatically, further research is warranted to confirm these possible clinically beneficial effects of CRT in this population.